Ticker brief
TEVA TEVA PHARMACEUTICAL-SP ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$36.44
1 day
-3.1%
14 days
-0.9%
mkt cap
$40.3B
signals 14d
17
authors 14d
12
crowd 14d
-0.7σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 35% cheap · 19 pctile own 1y | IV/HV 0.98× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | -0.003 85 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.86 thin | 5-session Δ -0.20 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-03-17 (z=3.0) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now -0.01 (−1 bearish … +1 bullish)
Who spoke12
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @StableBread | A | -1.09 | 4 | +0.16 |
| @tenet_research | C | -0.96 | 2 | +0.50 |
| @BioStocks | C | -3.02 | 2 | +0.08 |
| @ramahluwalia | A | -2.45 | 1 | +0.20 |
| @newsinvesting | C | · | 1 | +0.50 |
| @ShakePryzby1 | B | +0.06 | 1 | +0.60 |
| @HeadedNine | B | +0.53 | 1 | +0.70 |
| @StockMKTNewz | C | +0.59 | 1 | +0.25 |
| @KontraInvest | A | +0.93 | 1 | -0.10 |
| @CrweWorld | C | · | 1 | -0.10 |
| @BPharmCatalyst | C | · | 1 | +0.10 |
| @fwpharma | B | +0.98 | 1 | -0.10 |
Recent signals17of 17 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @fwpharma | -0.10 | Teva bids up to 125M for BioXcel neuroscience assets in a bankruptcy sale. | — | tweet ↗ |
| 2026-08-28 | @BPharmCatalyst | +0.10 | BTAI entered Chapter 11 and named Teva stalking-horse bidder for nearly all assets | — | tweet ↗ |
| 2026-08-28 | @CrweWorld | -0.10 | Teva announces a proposed acquisition of a BioXcel neuroscience product. | — | tweet ↗ |
| 2026-08-28 | @BioStocks | +0.05 | Teva could acquire worldwide asset rights for $57.5M upfront plus up to $67.5M contingent payments. | — | tweet ↗ |
| 2026-08-28 | @KontraInvest | -0.10 | Reports TEVA will acquire a neuroscience product. | — | tweet ↗ |
| 2026-08-28 | @BioStocks | +0.10 | BTAI files for bankruptcy and enters an asset-sale agreement with Teva. | — | tweet ↗ |
| 2026-08-25 | @StableBread | +0.15 | Argues Teva's patent filings do not threaten RVPH and may signal partnership or acquisition interest. | -4.4% | tweet ↗ |
| 2026-08-25 | @StockMKTNewz | +0.25 | Lists stocks that reached new 52-week highs; output capped at six tickers. | -4.4% | tweet ↗ |
| 2026-08-25 | @HeadedNine | +0.70 | Discloses being on board TEVA now after previously missing the entry. | -4.4% | tweet ↗ |
| 2026-08-25 | @StableBread | +0.20 | Uses Teva patent precedents and biotech acquisitions to frame major strategic upside for RVPH. | -4.4% | tweet ↗ |
| 2026-08-24 | @StableBread | +0.05 | Teva's long-running patent work on RVPH's drug is framed as evidence of strategic interest. | -1.3% | tweet ↗ |
| 2026-08-20 | @ShakePryzby1 | +0.60 | Uses earnings reactions to identify healthcare and other non-AI leaders for quarterly portfolio construction. | -1.0% | tweet ↗ |
| 2026-08-20 | @StableBread | +0.25 | Presents RVPH as deeply undervalued despite delays, citing patent extension and possible TEVA strategic interest. | -1.0% | tweet ↗ |
| 2026-08-19 | @newsinvesting | +0.50 | FDA accepted Teva's ecopipam NDA for Tourette syndrome treatment. | -2.7% | tweet ↗ |
| 2026-08-19 | @tenet_research | +0.50 | Reports FDA acceptance of Teva's ecopipam NDA for regulatory review. | -2.7% | tweet ↗ |
| 2026-08-19 | @tenet_research | +0.50 | Reports FDA acceptance of Teva's ecopipam NDA for regulatory review. | -2.7% | tweet ↗ |
| 2026-08-15 | @ramahluwalia | +0.20 | Argues portfolio disclosures reveal useful rotations, including TEVA/WDC discovery and PLTR selling. | -0.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.